Jan 23, 2023 | 2023, Events, Scientific
Philogen announces its attendance at the European Bispecific and Multispecific Antibody congress in Amsterdam. Dr. Roberto De Luca (Head of Antibody Therapeutics at Philochem) is giving a lecture on the 23rd of February 2023 entitled “Engineering Antibody-Cytokine...Jan 23, 2023 | 2023, Events, Scientific
Philogen announces its attendance at the Annual Next-Gen Immuno-Oncology Conference congress in London. Dr. Roberto De Luca (Head of Antibody Therapeutics at Philochem) is giving a lecture on the 9th of March 2023 entitled “Engineering Antibody-Cytokine Fusion...Dec 7, 2022 | 2023, Events, Scientific
Philogen announces its attendance at World ADC2023 in London. Dr. Samuele Cazzamalli (Head of Small Molecule Therapeutics at Philochem) is giving a lecture on the 14th of March 2023 entitled “Enhancing the Therapeutic Index of ADCs to Penetrate Solid Tumours:...Dec 1, 2022 | 2022, Press Releases, Scientific
The management team to hold a Webinar on Dec 1, 2022, at 10:00 ET / 15:00 GMT / 16:00 CET (Please find the link for the webinar here). Corporate_Update_Dec 1Nov 18, 2022 | 2022, Press Releases, Scientific
The study describes the development of a novel anti-PD-1 antibody that shows potent blockade of PD-1 with a different recognition mechanism compared to anti-PD-1 antibodies that have recently reached the market. For more detailsNov 11, 2022 | 2022, Press Releases, Scientific
The study describes the discovery of GCPIII as the protein responsible for the accumulation of conventional PSMA targeting agents in healthy organs. More details
Recent Comments